Company news

Milestone Pharmaceuticals Inc. news in 2024

Milestone Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.

View company

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

November 11, 2024

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

September 3, 2024

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

August 25, 2024

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

August 7, 2024

Milestone Pharmaceuticals Refreshes Board of Directors

July 14, 2024

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 28, 2024

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

May 21, 2024

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

May 12, 2024

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024

May 1, 2024

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

April 16, 2024

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

April 7, 2024

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

March 31, 2024

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

March 27, 2024

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

March 20, 2024

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

February 28, 2024

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

February 27, 2024

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

February 25, 2024

Decks in 2024